1 Intraoperative Plasma Proteomic Changes in Cardiac Surgery: In Search of

2 Biomarkers of Post-operative Delirium

- 3
- 4 Kwame Wiredu^{1,2}, Sean O'Connor³, Erika Monteith³, Brooke Brauer⁴, Arminja N.
- 5 Kettenbach^{4,5}, Hildreth R. Frost^{5,6}, Shahzad Shaefi^{3,7}, Scott A. Gerber^{1,4,5}
- 6
- ⁷ ¹Department of Molecular and Systems Biology, Geisel School of Medicine at
- 8 Dartmouth, Lebanon, NH
- ⁹ ²Program in Quantitative Biomedical Sciences, Geisel School of Medicine at Dartmouth,
- 10 Lebanon, NH
- ¹¹ ³Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess
- 12 Medical Center, Boston MA
- ⁴Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth,
- 14 Lebanon, NH
- ⁵Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH
- ⁶Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth,
- 17 Lebanon, NH
- ¹⁸ ⁷Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School,
- 19 Boston MA
- 20
- 21 Corresponding author: Scott A. Gerber, Professor of Molecular and Systems Biology,
- 22 <u>Scott.A.Gerber@Dartmouth.Edu</u>, 1 Medical Drive, Lebanon NH 03756
- 23

- 24 **Running title**: Biomarkers of Delirium After Cardiac Surgery
- 25

26	Abbreviations: CABG – coronary artery bypass grafting; CAM – confusion assessment
27	method; CPB – cardiopulmonary bypass; POD – post-operative delirium; SPS-MS –
28	synchronous precursor selection – mass spectrometry; TMT – tandem mass tagging
29	
30	Keywords: biomarker discovery, delirium, mass spectrometry, plasma, proteomics
31	
32	Word count:
33	Abstract: 202 / 200
34	Clinical significance: 159 / 200
35	Text: 4951
36	References: 2146
37	Figures and Table: 1195
38	
39	
40	
41	
42	
43	
44	
45	
46	

47 Abstract

48 Purpose

- 49 Delirium presents a significant healthcare burden. It complicates post-operative care in
- 50 up to 50% of cardiac surgical patients with worse hospital outcomes, longer hospital
- 51 stays and higher overall cost of care. Moreover, the nature of delirium following cardiac
- 52 surgery with cardiopulmonary bypass (CPB) remains unclear, the underlying
- 53 pathobiology is poorly understood, status quo diagnostic methods are subjective, and
- 54 diagnostic biomarkers are currently lacking.
- 55

56 **Objective**

- 57 To identify diagnostic biomarkers of delirium and for insights into possible neuronal
- 58 pathomechanisms.
- 59

60 Experimental design

61 Comparative proteomic analyses were performed on plasma samples from a nested

62 matched cohort of patients who underwent cardiac surgery on CPB. A targeted

63 proteomics strategy was used for validation in an independent set of samples.

- Biomarkers were assessed for biological functions and diagnostic accuracy.
- 65

66 **Results**

47% of subjects demonstrated delirium. Of 3803 total proteins identified and quantified

68 from patient plasma samples by multiplexed quantitative proteomics, 16 were identified

as signatures of exposure to CPB, and 11 biomarkers distinguished delirium cases from

- non-cases (AuROC = 93%). Notable among these biomarkers are C-reactive protein,
- 71 serum amyloid A-1 and cathepsin-B.
- 72

73 Conclusions and clinical relevance

74 The interplay of systemic and central inflammatory markers shed new light on delirium

75 pathogenesis. This work suggests that accurate identification of cases may be

76 achievable using a panel of biomarkers.

77

78 Statement of Clinical Relevance:

79 The acute implication of delirium is well-documented, yet the true extent of the

80 consequences beyond the immediate post-operative period has yet to be fully known.

81 Despite its impact on the geriatric population, delirium remains underdiagnosed.

82 Correctly identifying cases remain a challenge in clinical practice: the arbitrary and

83 subjective nature of current diagnostic tools, such as the confusion assessment method,

84 underscores the urgent need for diagnostic biomarkers. The clinical usefulness of

85 delirium biomarkers extent beyond the objective identification of cases. Delirium

86 biomarkers will also be useful for risk stratification, long-term follow-up of patients and

87 may offer insights into possible etiologies that underpin the condition. In this report, we

88 found systemic markers of inflammation with well-established association with delirium,

as well as new biomarkers that shed new light on the condition. Although validation in a

90 larger cohort is the necessary next step, our efforts lay the groundwork for future studies

91 and highlight new frontiers in delirium research yet to be explored.

92

93 Introduction

94 Delirium remains under-diagnosed in clinical practice[1-3]. Characterized by acute 95 fluctuations in consciousness, deficits in attention and impairments in cognition not 96 explained by a pre-existing neurocognitive disorder, delirium is etiologically 97 heterogenous with a particularly high incidence after cardiac surgery [4, 5]. Following 98 cardiac surgery, it complicates post-operative care in up to 50% of patients with 99 increased length of hospitalization, increased mortality and higher overall cost of 100 care[6]. In the long term, post-cardiotomy delirium patients are at increased risk of many 101 complications, including re-admissions [7], cognitive decline [8-11], functional 102 impairments [12], and stroke [13, 14], to mention a few. Clearly, delirium presents a 103 significant healthcare burden on society. The true extent of the consequences beyond 104 the immediate post-operative period remains unknown. Thus, the accurate identification 105 of subjects for optimal care in the immediate post-operative period and for long-term 106 follow-up is likely to exert a significant positive impact on patient care and costs if 107 implemented successfully.

108

Unfortunately, many patients with delirium are missed [15, 16], an observation that is
partly due to the subjective and variable nature of the current diagnostic approach.
Efforts to improve recognition and accurate case identification has seen a steady rise in
recent years, although a small fraction of these attempts has focused on biomarker
discovery. Most of these biomarker studies also employed targeted quantification
strategies for a sub selected list of genes or proteins, an approach that is inherently

biased and blinded to potentially novel factors involved in the etiology or consequencesof delirium [17][manuscript].

117

118 Challenges with delirium biomarker discovery are due, in part, to the lack of clarity regarding the underlying pathophysiology of the condition. While a one-size-fits-all 119 120 explanation of delirium may be oversimplified, neuroinflammation induced by systemwide activation of an inflammatory cascade remains the prevailing mechanistic 121 122 hypothesis[18, 19]. This is supported by recent untargeted and semi-targeted 123 approaches that sought to study the proteome of human biofluids [20-27], although 124 neuroendocrine and circadian dysregulation have also been reported[18]. The emerging 125 focus on signaling and inflammatory markers necessitate biomarker discovery 126 approaches that focus on the low-abundance proteome, using analytical platforms with 127 the multiplexing capability and the requisite sensitivity to detect small changes in 128 proteomic signatures.

129

In the present work, we comprehensively profiled the plasma proteome of subjects at 130 131 baseline and post-cardiotomy for an untargeted analysis of the plasma proteome. We 132 included abundant protein immunodepletion and peptide fractionation to enhance signal from the low abundance plasma proteome. Using independent set of samples, we 133 134 validated candidate biomarkers at three time points (at baseline, post-bypass and post-135 operative) in order to understand the changing trajectories of these biomarkers over 136 time as they relate to case identification. Finally, we demonstrate the diagnostic 137 potential of a panel of candidate biomarkers, the accuracy of their use in discriminating

- 138 cases from non-cases and the temporal association between intra-operative events and
- 139 changes in biomarker levels.

140

141

142

146

- 143 **Results:**
- 144 Clinical Profile of Study Participants

Subjects (n = 15) were selected from the parent study[28], which was a parallel group

randomized controlled trial that enrolled 100 patients at Beth Israel Deaconess Medical

147 Center (BIDMC), between July 2015 and July 2017. Delirium cases and non-delirium

148 controls were age- and sex-matched (**Table 1**). There was no difference in baseline

neurocognition between cases and non-cases, and the proportion of patients who

150 received hyperoxic intraoperative treatment was comparable. There were no significant

151 differences with regards to demographics, medical co-morbidities, pre-operative

152 medications, or surgical characteristics. Details of the clinical characteristics of study

153 subjects were reported previously[28].

154

155 Discovery Phase of Biomarker Workflow

Using a multiplexed isobaric tagging (TMT)-based design, plasma samples at baseline and on post-operative day 1 from 7 delirium cases (CAM+) and 8 non-delirium controls (CAM-) were comprehensively profiled (**Figure 1**). For precision, samples selected for the discovery phase of the study were analyzed in duplicates, for a total n = 60 samples, which necessitated the analysis of seven separate, batched multiplexes. To control for technical variation between batches, two channels in each of the seven 11-plex TMT
sets were reserved as bridge samples using equal amounts of a pooled plasma sample.
We fractionated the TMT-labeled peptides using off-line HPLC on a pentafluorophenyl
(PFP) column as described previously[29] into 48 fractions, which were subsequently
concatenated into 12 and analyzed by LC-MS/MS on an Orbitrap Fusion Lumos Tribrid
instrument platform.

167

168 A collective total of 17,540 unique peptides from 3,803 proteins were identified from all seven multiplexes. An analysis of the number of proteins from each batch, separated 169 170 into a binary group based on the corresponding number of peptides used in the 171 identification of these proteins, demonstrates that our data are clearly dominated by so-172 called "one-hit proteins," or proteins identified by a single peptide (Figure 2A). Often, 173 single-peptide protein identifications are excluded from downstream analysis due to the 174 increased risk of false protein identifications associated with single-peptide protein 175 assignments. However, excluding all one-hit proteins can be a huge informational cost as some of these proteins may be biomarkers of interest. 176

177

178 One-hit Proteins and Deep Learning for Confident Protein Identification:

To examine this further, we differentiated one-hit proteins identified only in single batches of experiments from those identified consistently across multiple batches. We reasoned that identified one-hit proteins consistently identified in multiple independent analyses are less likely to be false identifications, especially if their consistent identification is based on the same unique peptide. These one-hit proteins warrant

184	additional peptide-centric information for protein inference beyond the sequences of the
185	single peptides. Figure 2B displays the number of proteins identified in any given
186	number of collective batches. Of the 3803 total proteins (figure 2B, cumulative batch
187	\leq 7), 51% (<i>n</i> = 1941 proteins) were identified based on a single peptide. While the
188	number of proteins identified based on 2 or more peptides increased with increasing
189	number of collective batches, the number of one-hit proteins remained fairly consistent.
190	In particular for cumulative batches three to seven, we found 1698 one-hit proteins that
191	were present in all of them.

192

To enhance the confidence in the identity of these one-hit proteins and minimize false 193 194 positive identifications, we employed chromatographic retention time (RT) as additional 195 peptide-centric information and orthogonal to their identification by tandem mass 196 spectrometry. Here, we considered a peptide as confidently identified if, in addition to being a high-scoring peptide by PSM, the observed RT also falls within the RT window 197 198 expected for that peptide and its corresponding experimental batch conditions. For 199 example, K.GTEAAGAMFLEAIPMSIPPEVK.F, a unique peptide from alpha-1-200 antitrypsin, A1AT HUMAN (figure 2C, supplemental figure 1, blue rectangles) shows 201 consistent RTs, regardless of the experimental batch or sample fraction the peptide was detected. On the other hand, K.GTEDFIVESLDASFR.Y (figure 2C, supplemental 202 203 figure 1, red rectangles) is the only peptide-evidence that translocon-associated protein 204 subunit alpha, SSRA_HUMAN – a one-hit protein – was detected in experimental batch 205 2.

206

207 To determine the RT window expected for these single peptides given the LC-MS 208 conditions of their respective experimental batches, we trained a deep learning-based 209 RT predictor, the DeepRT+ [30], using 80% of the RT of consistently identified peptides 210 for a given experimental batch. We tested the prediction accuracy of the DeepRT+ 211 model with the remaining 20% of the training data and subsequently used the final 212 model to predict the RT of one-hit proteins. We assessed performance of the RT prediction using the coefficient of determination, R^2 , and $\Delta t95\%$, the minimum time 213 window containing deviations between the observed and the predicted RT for 95% of 214 215 the peptides (Figure 2D and Supplemental Figure 2). We found the RT of 495 unique 216 one-hit peptides fell within the Δ t95% metric (**Table 2**) and were thus included to a final 217 total of 1731 proteins used for downstream analysis (Figure 2E). The dynamic range of 218 all proteins spans 6.3 orders of magnitude and confirms signal from a wide range of 219 abundances in the plasma proteome (Figure 2F).

220

221 Protein Feature Selection and Differential Abundance Analyses

222 To determine the subset of these 1731 proteins that are most important in discriminating 223 plasma profiles of cases and from non-cases and between baseline and post-operative 224 timepoints, we employed an elastic net regularized regression approach[31]. We found 225 47 and 64 proteins as signatures of surgical exposure and of delirium, respectively. 226 Principal component analysis (PCA) of study subjects using the subset of protein 227 features demonstrates that delirium cases cluster separately, with marginal overlap 228 between non-delirium controls and baseline samples (Figure 3A). Additionally, plasma 229 profiles of cases and non-cases are clearly separable post-operatively, although they

were indistinguishable at baseline (**Figure 3B**). This strongly suggests a temporal

- 231 relationship between post-operative changes in proteomic signatures and subjects'
- surgical exposure and/or related intra-operative physiological events.
- 233

Furthermore, we quantified the extent of changes in biomarker levels before and after surgery (**Figure 3C**) and between cases and non-cases (**Figure 3D**). When using the proteins identified as a signature of delirium (**Figure 3D**), we observed a diagnostic accuracy of 93% in discriminating cases from non-cases (**Figure 3E**). Functional analysis of the biomarker panel for biological processes shows acute inflammatory response and activation of the immune system as the most significantly enriched functional pathways, predominantly in the extracellular region (**Figure 3F** and

241 Supplemental Figure 3).

242

243 Biomarker Verification

244 For further evaluation of peri-operative proteomic differences between cases and non-245 cases, an independent set of plasma samples was used to verify biomarkers discovered 246 a priori (Figure 4). Here, we used parallel reaction monitoring (PRM) as the targeted 247 approach and employed label-free quantification (LFQ) as orthogonal methods different 248 from the TMT approach used in the discovery phase. To ascertain the degree to which 249 changes in protein concentration in the complex background of plasma are quantifiable, 250 we artificially modified six biological replicates of a pooled plasma sample with the 251 addition of exogenous proteins: (1) equal amounts of a non-human 252 (Schizosaccharomyces pombe) homolog of the serine/threonine-protein kinase Chk2

(CDS1 in *S. pombe*); and (2) increasing concentrations of heavy-labeled AQUA
peptides[32, 33] of human condensin-2 complex subunit H2 (CNDH2). From this
experiment, we estimate a limit of quantification of ~1fmol on column (Figure 5A), with
negligible impact on target protein quantification due to matrix effects from large (16fold) variations in the concentration of a non-target protein in the matrix (Supplemental
Figure 4).

259

260 For candidate biomarker verification, we developed parallel reaction monitoring (PRM) 261 methods through an iterative optimization process (Supplemental Figure 5). We 262 monitored 153 unique peptide sequences (212 total precursor ions including the 263 observed range of charge states) from the union of 18 differentially abundant proteins 264 as PRMs that were distributed across the entire LC-PRM elution gradient (Figure 5B). 265 For example, we monitored the abundance of the peptide ESDTSYVSLK from C-266 reactive protein as a doubly-charged ion via five individual y-ions in our PRM method 267 via Skyline (Figure 5C) in each verification sample. The PRM methods we employed 268 required the following minimum criteria for peptide quantification: a consistent minimum of 5 transitions in all samples, a minimum dot-product of 95% and manual inspection of 269 270 all peaks for interference-free co-eluting transitions with distinct peak boundaries. 65 271 precursors from 13 proteins met these criteria for downstream analysis (Supplemental Table 3). Unsupervised clustering based on the quantification of these candidate 272 273 biomarkers shows that post-operative samples aggregate separately from post-bypass 274 and baseline samples (Figure 5D). This is further confirmed by statistical comparison of

biomarker levels between the sampling timepoints (**Figure 5E** and **Supplemental**

276 **Figure 6**).

277

278	Seven biomarkers (A2GL, AACT, CH3L1, CRP, LBP, MA1A1 and SAA1/SAA2) were
279	significantly increased at post-operative day one (PO1) relative to baseline in this
280	validation cohort. Four razor peptides were shared between SAA1 and SAA2. However,
281	no peptides unique to either SAA1 or SAA2 met the minimum quantification criteria for
282	PRM verification. Similarly, none of the precursor peptides of CAH3, EFNA1, FGL1 or
283	PEPA4 met PRM quantification criteria. Regardless of statistical significance, we
284	observe that these candidate biomarker levels show a consistent increase in abundance
285	between baseline and PO1 (Supplemental Table 3). This panel of differentially
286	abundant candidate biomarkers yields a discriminatory power of 96% (84.9 – 100%)
287	between cases and non-cases (Figure 5F).
288	
289	
290	

291 Discussion

This unbiased proteomic analysis of samples from a prior nested case-control study is the deepest unbiased plasma proteomic profiling for potential biomarkers of delirium to date. We employed a rectangular biomarker workflow[34] to both discover and verify biomarkers of post-operative delirium on a single mass spectrometry platform without the use of traditional affinity-based verification methods. Dominated by one-hit wonders, our focus on the low-abundance proteome presented us with the challenge of protein inference, for which we applied deep learning to recover pertinent orthogonal peptide
chemical information and salvage a significant number of these one-hit proteins.
We identified 3808 proteins by isobaric quantitative multiplexed proteomics, 16 of which

301 were differentially abundant post-operatively from baseline levels, and 11 of which were

302 differentially abundant in cases relative to controls. This includes proteins with well-

documented associations with delirium, such as CRP, CH3L1, AACT, TIMP1, as well as

new ones not previously associated with delirium, including SAA, CATB and PEPA3.

305 Using an independent set of samples, we attempted to verify the union of these

306 candidate biomarkers and found a 96% accuracy in correctly identifying delirium

307 patients for those for which quantification was possible. Collectively, our findings show a

308 temporal association between intra-operative events (i.e., surgical insult, administered

anesthesia, etc.) and proteomic changes associated with phenotypic delirium.

310

311 The prevailing mechanistic hypothesis of delirium is one of acute neurocognitive 312 disruption triggered by system-wide inflammation[18, 19]. In our study, functional 313 analysis of the post-operatively dysregulated biomarkers suggests a system-wide 314 activation of the inflammatory cascade and related immunological reactions. Data on 315 the associations between delirium and acute-phase reactants (APR) such as CRP is 316 ubiguitous[20, 35-38]. Although known APRs correlate well with the severity of 317 inflammation, their usefulness as biomarkers is limited as they are not specific to 318 delirium. We, however, found additional acute-phase reactants that may shed a new 319 light on delirium.

320

321 Human serum amyloid A (SAA) is a collective name for a group of polymorphic proteins 322 functionally associated with high-density lipoprotein (HDL). By the regulation of their 323 synthesis, they are grouped into the acute phase isotypes (a-SAA: SAA1, SAA2 and 324 SAA3) and the constitutive isotype (c-SAA: SAA4)[39, 40]. Although predominantly 325 secreted by the liver, extra-hepatic production occurs in the brain and may be more 326 relevant in neurocognitive disorders such as Alzheimer's disease[41-44]. SAA has 327 cytokine-like effects which likely provokes blood brain barrier (BBB) dysfunction, 328 induces depressive-like behavior in mice and may impair cognition in human 329 subjects[45-48]. In the present study, we found SAA1 and SAA2 were both upregulated 330 post-operatively in delirium cases by over 5 folds (p value < 0.001). This is the first 331 mention of SAA in the context of delirium and warrants further studies to formally 332 credential this association with the condition.

333

The cysteine protease cathepsin B (CATB) has previously been quantified as an AD-334 335 related biomarker and correlates with mini-mental state examination (MMSE) scores 336 [49-52], but its association with delirium is unknown. It is an inflammasome that 337 promotes IL-1beta maturation and secretion[52]. It also has a beta-secretase activity, 338 capable of cleaving amyloid precursor protein into amyloid beta [53]. Given that cases 339 and non-cases in our study were matched by baseline neurocognition and tMOCA 340 scores were statistically controlled for, upregulation of CATB in delirium cases may 341 indicate a common pathophysiological starting point in the continuum of neurocognitive disorders, of which delirium and AD are a part. Generally recognized as the first enzyme 342 343 to be discovered, pepsin (PEP-A) is the native acid protease of the stomach[54]. Blood

344 pepsin is an established biomarker of gastric mucosal integrity, and plasma levels 345 correlate with the degree of mucosal damage[55-58]. Cardiac surgery and CPB places 346 enormous physiological stress on the body. Through the cholinergic anti-inflammatory 347 reflex, the body attempts to ameliorate the stress by increasing vagal tone[59-62] which 348 manifests as gastric acid production. Normally, small amounts of secreted pepsin ($\sim 1\%$) 349 may be found in blood and urine[63], but with increased acid production, this proportion 350 may be higher. In the discovery phase of our study, differentially abundant PEP-A levels 351 in cases relative to non-cases (1.64-fold increase, p value < 0.001) despite pre-352 operative proton-pump inhibitor administration in the study subjects suggests a peculiar association between plasma PEP-A levels and delirium. At present, we are unable to 353 354 explain the relationship, if any, between increased vagal tone and neuroinflammation.

355

The independent association between CPB and delirium remains an ongoing debate 356 357 and data on the relationship is conflicting. On the one hand, the use and duration of 358 extracorporeal circulation is reported to increase the risk of delirium[64-66]. Some 359 authors, on the other hand, have reported no associations between delirium incidence 360 and CPD duration[67, 68]. In our cohort, there was no statistically significant difference 361 in aortic cross-clamp time or duration of bypass between delirium cases and non-362 cases.[28] To determine the impact of CPB in our cohort, we compared post-operative 363 plasma profiles to baseline regardless of the case/non-case status of subjects. We 364 found 16 dysregulated proteins, most of which have been characterized as non-specific 365 markers of surgical exposure[69-71]. A striking observation in our study is the 366 similarities in proteomic signatures between cases and non-cases at baseline, despite a

clear difference at post-operative day one. Previous studies have shown that postoperative delirium cases are likely to be in a heightened pre-operative inflammatory
state [20, 37, 60, 72-75], which makes them more vulnerable to intraoperative stressors.
In our study, similarities in the levels of identified biomarkers at baseline suggests
otherwise.

372

373 The main strength of the present study is in its unbiased, hypothesis-generating

374 approach to identify potential biomarkers of delirium. This lays the groundwork for future

375 studies and highlights new frontiers in delirium research yet to be explored.

376 Translational utility from the research bench to the patients' bedside requires that the 377 biomarker readout in the discovery phase is independent of the measurement approach 378 used for their discovery[76]. For this reason, we validated discovered biomarkers using 379 label-free quantification, which is orthogonal to the TMT-based measurements in the 380 discovery phase of our study. Our choice of PRM-MS over traditional affinity methods 381 for validation (e.g., ELISA) is further premised on the fact that affinity methods are semi-382 quantitative with inter-operator variability in quantification, have limited dynamic range 383 and require larger amounts of sample. In addition to the requirement for peptide 384 antigenicity, antibody cross-reactivity limits multiplexing (i.e., how many proteins can be 385 validated at a time)[77]. All proteins needing validation require antibodies, a step that 386 takes considerable amount of time to develop and can be cost-prohibitive if commercial 387 options are not available [78]. This, in fact, is a long-standing bottleneck in clinical biomarker workflow[79]. 388

389

390 Our study is, however, not without limitations. First, sample sizes for both the discovery 391 and validation phases may have limited statistical power in detecting differences in the 392 levels of many other biomarkers. In our cohort, the CAM test was administered daily 393 after surgery. In our statistical analysis, we did not correct for the effects of retesting on 394 repeated test administration in this cohort. In the discovery phase, our interest in the 395 low-abundance plasma proteome required an immunodepletion step to remove the 396 majority of the top 14 most abundant plasma proteins. The extent to which this 397 experimental step contributed to the removal of other proteins through their specific or 398 non-specific binding was not ascertained. Although isotypes SAA1 and SAA2 each had 399 unique peptides in the discovery phase, only the razor peptides met the criteria for 400 quantification in the validation phase and were thus undistinguishable. Similarly, 401 peptides from CAH3, EFNA1 and PEPA3 did not meet the minimum quantification 402 criteria for verification by PRM, and peptides from FGL1 were not detected at all in any 403 of the verification samples by PRM.

404

In summary, diagnostic biomarkers of delirium are urgently needed for accurate case 405 406 identification, long-term risk stratification and for molecular characterization of delirium. 407 In this study, we discovered a panel of biomarkers through the unbiased comparative analyses of baseline and post-operative plasma samples of delirium cases and non-408 409 cases. We underscored the importance of brain-specific biomarkers such as SAA and 410 CATB and their possible role in the pathophysiology of delirium. In the long-term, it is in our research interests to rigorously test their associations with delirium and ascertain 411 412 how these biomarkers change over time in a larger independent cohort.

414 Acknowledgments

- 415 Funding support for this work was supplied by the Burroughs Wellcome training grant to
- 416 KW, the National Institutes of Health (R01 GM122846) to SAG, and K08 GM134220
- and R03 AG060179 to SS. The heavy-labeled peptides of CNDH2 condensin subunit
- 418 were also provided by Dr Giovanni Bosco (Dartmouth College).

436

437 Materials and Methods:

438 Study Design and Patient Enrollment:

439 Subjects in this nested case-control study were selected from the parent study, a 440 randomized double-blind trial conducted on subjects who underwent coronary artery 441 bypass grafting (CABG) with cardiopulmonary bypass (CPB) between July 2015 and July 2017 at the Beth Israel Deaconess Medical Center (BIDMC) in Boston MA. The trial 442 443 was registered with ClinicalTrials.gov (NCT02591589, https://clinicaltrials. 444 gov/ct2/show/NCT02591589, principal investigator: Shahzad Shaefi, registration date: 445 October 29, 2015). Institutional review board (IRB) approval 2014P000398/33 was amended for the purposes of this current study on 09/17/2021 by the Committee on 446 447 Clinical Investigations at the BIDMC. Details of enrollment, subject randomization and 448 treatment allocation in the parent study are published elsewhere [28, 80]. Briefly, 449 patients aged 65 years or older who were booked for elective CABG requiring CPB 450 were eligible. The primary objective was to examine the temporal relationship between 451 intra-operative oxygen treatment and post-operative neurocognitive function as 452 measured by the telephone-based Montreal Cognitive Assessment (tMOCA) score. 453 Patients were assessed for delirium as a secondary endpoint using the confusion assessment method (CAM). Patients were excluded if they were undergoing emergent 454 455 CABG, if they required single-lung ventilation, CABG without CPB, intraoperative 456 balloon counter-pulsation or mechanical circulatory support. All patients provide informed consent. 15 subjects were randomly selected for proteomic profiling in this 457 458 nested case-control study. Because quantitative studies on the effect size of delirium

459 biomarkers using mass spectrometry is largely unexplored, formal power analysis was460 not done.

461

- 462 Sample Collection:
- 463 Whole blood samples at baseline, post-bypass (P-BP) and on post-operative day one
- 464 (PO1) were collected into 4mL EDTA-treated tubes (BD Diagnostics) and centrifuged
- immediately at 200g at room temperature for 10 min. Resulting plasma was stored at -
- 466 80°C until they were thawed for aliquots used here for proteomic profiling.

467

- 468 Chemicals and Reagents:
- 469 All LC-grade chemicals are marked with asterisk (*): Dithiothreitol (DTT), 4-(2-
- 470 hydroxyethyl)-1-piperazineethanesulfonic acid (EPPS), Tris (hydroxymethyl)
- 471 aminomethane (Tris), formic acid* and acetonitrile* were purchased from Sigma-Aldrich.
- 472 Methanol* was obtained from Fisher. Trypsin Protease, SDS, 2-iodoacetamide (IAA),
- 473 High Select Top14 Abundant Protein Depletion Mini Spin Columns and TMT 11 plex kit

474 were acquired from Thermo Fisher Scientific.

475

476 Sample Preparation analysis:

477 Sample Immunodepletion:

478 Buffer exchange on single-use High Select Top14 Abundant Protein Depletion mini-spin

- columns (ThermoFisher Scientific) was performed twice using 200 µL of 50mM Tris [pH
- 480 8.1] / 50mM NaCl. 10 μL of each plasma sample was applied to the mini-columns,
- 481 incubated at -4°C with gentle end-over-end mixing for 15 min, according to

manufacturer's instructions. Flowthrough were collected by centrifugation at 1000*g* for 2
min into 2mL Eppendorf tubes. Concentrations of the depleted samples were obtained
using the Pierce BCA Protein Assay Kit (Thermo Scientific) at 562 nm absorbance per
manufacturer's instructions.

486

487 Digestion and Labelling for Biomarker Discovery

488 Depleted samples were treated with SDS (2% final) and DTT (2mM final) for denaturing 489 at 75°C for 15 min. Samples were cooled to room temperature before alkylation with IAA (7mM final) at room temperature in darkness for 30 min and guenched with DTT 490 491 (additional 2mM final) for 10 minutes. Proteins were isolated by single-pot solid-phaseenhanced sample preparation (SP3) and digested to peptides in EPPS buffer overnight 492 at 30°C with 1:50 w/w trypsin (Promega[™]). Tryptic peptides were labeled with TMT-11 493 494 plex reagent for 1 hr according to manufacturer's instructions. Two channels in each set 495 of TMT-11 plex were reserved for pooled plasma to be used as bridge samples for 496 technical control. Labeling efficiency of at least 95% was confirmed on a 1-hr gradient before pooling. Labeled tryptic peptides were then desalted on an OASIS µHLB 497 (Waters) and subsequently dried by vacuum centrifugation prior to off-line HPLC 498 499 fractionation on a pentafluorophenyl (PFP) column as described previously [29]. 48 500 fractions were concatenated into 12 fractions for LC-MS/MS analysis. All samples were 501 prepared in duplicates.

502

503

504

505 Digestion for Biomarker Validation

506	Equal amounts of recombinant purified CDS1 protein were added to each depleted
507	sample before treatment with SDS (2% final) and DTT (2mM final) for denaturation and
508	alkylation as described above. Proteins were isolated by single-pot solid-phase-
509	enhanced sample preparation (SP3) and digested to peptides in 50mM ammonium
510	bicarbonate buffer overnight at 30°C with 1:50 w/w trypsin (Promega TM). In a separate
511	experiment to check for signal linearity, increasing concentrations of heavy-labeled
512	peptides of CNDH2 condensin subunit were added to the samples at this point. Tryptic
513	peptides were desalted on an OASIS μHLB (Waters) and dried by vacuum
514	centrifugation. All samples were run in duplicates.
515	
516	
517	LC-MS/MS
518	All data were acquired on an Orbitrap Fusion Lumos Tribrid instrument (ThermoFisher
519	Scientific, San Jose, CA) equipped with EASY-nanoLC 1200 ultra-high pressure liquid
520	chromatograph (ThermoFisher Scientific, Waltham, MA). Dried peptides were
521	resuspended in 5% methanol / 1.5% formic acid and injected onto a 35-cm long / 100-
522	μ m (inner diameter) in-house pulled analytical column packed with Reprosil C18
523	stationary phase particles. Discovery samples were separated on 120-minute gradient,
524	and validation samples on a 60-min gradient, at 350nL/min flow rate. Acquisition
525	parameters included 120,000-resolution at MS1, AGC target value of 5.0×10^5 , scan
526	range of 350 – 1250 m/z and maximum injection time of 100ms. For the TMT-labeled
527	peptides, the top eight MS2 peaks were selected for further fragmentation at 55%

normalized high-collision energy (HCD) via SPS-MS3 for quantification of reporter ions
in the scan range of 110 – 500 m/z. For the label-free peptides in the validation phase,
MS2 scans were generated at 30,000 resolution and AGC value of 2.5×10⁵, using 30%
normalized collision energy (HCD).

533 Bioinformatics

534 Peptide Spectral Matching:

535 Acquired data (in .raw format) were searched using COMET [81] against a target-decoy version of the human proteome (Uniprot, downloaded in 2020 and 2022, for the 536 537 discovery and validation phases respectively). The fasta for the validation phase was appended with sequences from CDS1_SCHPO. Search parameters included a mass 538 539 tolerance of 20ppm, maximum missed cleavages of 3, carbamidomethylation of 540 cysteine as fixed modification and oxidized methionine as variable modification. In 541 addition, the mass of 229.162932 Da was added to the N-termini and lysine residues of 542 all peptides as fixed modification for the TMT data. A false discovery rate (FDR) of 1% was applied at the peptide level and final list of PSMs were filtered using XCorr and 543 delta XCorr. All data were subsequently imported into R environment for statistical 544 545 computing (v4.1.1) and Python programing language (v3.8) for downstream analyses 546 [82, 83].

547

548 TMT Data Wrangling and Normalization (Discovery Phase):

549 After correcting for differential sample loading, the ratios of sample proteins to their 550 respective bridge proteins were computed. Here, data from bridge samples was used 551 for guality control and to correct for batch-to-batch technical variations. Values were 552 subsequently log-transformed and mean-centered. Data from all batches were 553 combined and analyzed for possible outlier observations using OutlierDM R Package. 554 Proteins were removed if their frequency of observation was less than half of all 555 samples. For one-hit wonders in each batch of experiment, a retention time (RT) 556 predicting model was built in Python using DeepRT+ as described by Ma, Ren [30]. Prediction performance was assessed with coefficient of determination (R²) and delta-557 558 t95% ($\Delta t_{95\%}$). $\Delta t_{95\%}$ is the minimum time window containing deviations between the 559 observed and the predicted RT for 95% of the peptides. Peptides with RT outside the 560 $\Delta t_{95\%}$ range were excluded from downstream analysis. Missing entries in the data were 561 imputed by making random draws from the left tail of the gaussian distribution of the 562 entire log-transformed data matrix (using -2.5 SDs from the mean, width = 0.3).

563

564 Protein Feature Selection and Differential Abundance Analyses

565 To determine the subset of protein features that differentiated cases from non-cases, or 566 postoperative expression profiles from baseline, Elastic Net algorithm was used [31]. 567 This is a regularization and feature selection method with good performance on high-568 dimensional data (i.e., an *n*×*p* data with very large *p* proteins but small *n* samples). 569 Elastic Net is insensitive to features that dominate the matrix (e.g., albumin) and likely 570 suppress signal from low abundance predictors and skew model coefficients. In 571 addition, Elastic Net is a good choice if overfitting and multicollinearity (or protein features that are highly correlated and essentially communicate the same information) 572 573 are a concern. Tuning parameters were achieved by grid optimization with a five-fold

nested cross-validation where the last fold was held out for testing. The average of
hyperparameters from all folds were computed and used to build the final model.

576

577 Using the subset of protein features, an unsupervised visualization of the data was achieved with principal component analysis (PCA). Hierarchical clustering was 578 579 employed to check for reproducibility of replicate samples and inherent sample clusters, 580 and together with a heatmap, the overall protein expression patterns. Here, clustering 581 was achieved using Ward's clustering algorithm.[84] Briefly, Ward's minimum variance 582 method begins with singleton clusters and recursively merges them by minimizing the 583 total within-cluster variance as the objective function. After this point, protein values for 584 any given biological replicates were summarized as means prior to differential 585 abundance analyses. Two-way comparison for differential abundance was achieved by 586 Student's *t*-test, assuming unequal variance. Differential abundance analysis was 587 visualized with volcano plots. Because statistical comparison was done for only a 588 subset of proteins, no correction for multiple hypothesis testing was done. Proteins were 589 deemed differentially regulated between conditions if there was a statistically significant *t*-test (*p* value cutoff \leq 0.05) and a log2 fold-change of at least ±1. This fold-change 590 591 cutoff was selected to prioritize a panel of biomarkers with significant changes between conditions that is unlikely to be due to chance. 592

593

594 PRM Label-free Data Procession (Validation Phase):

595 Raw files were imported into Skyline v21.2.0.369 [85]. Precursor peptides with

596 modifications other than carbamidomethylation of cysteine (as fixed modification) or

597	oxidized methionine (as variable modification) were excluded. Peptide quantification		
598	criteria was defined as follows: (1) consistently identified precursors across all validation		
599	samples, (2) with maximum of two missed cleavages, (3) a consistent minimum of five		
600	transitions, and (4) at least 0.95 dop-product with the spectral library of chromatograms.		
601	All peak boundaries were manually inspected for interference-free co-eluting transitions		
602	before peak areas were integrated at the MS2 level. For any given precursor peptide,		
603	the five most intense fragment ions in the m/z range of 120 – 1500 were used for		
604	quantification. Final dataset was exported as .csv and analyzed in R environment for		
605	statistical computing (v4.1.2; R Core Team 2021). No imputations were required in the		
606	validation data. Data was normalized by computing peak area ratios relative to		
607	CDS1_SCHPO to correct for run-to-run variations. For each protein biomarker, Kruskal		
608	Willis global test was first used followed by post-hoc Mann-Whitney U test for pairwise		
609	comparisons of the normalized peak areas between the different sample collection		
610	timepoints (baseline, post-bypass and post-operative day 1).		
611			
612			
613	Data accessibility statement:		
614	Datasets from the discovery and validation phases are available as supplemental		
615	material.		
616			
617			

619

618

620 Figure 1 Caption: Study Design and Biomarker Discovery Workflow

621	Biomarker discovery: a cohort of 15 subjects were selected from the parent study of 100
622	patients who underwent a non-emergent coronary artery bypass grafting (CABG) on
623	cardio-pulmonary bypass (CPB) as part of a previously published clinical trial (1,2).
624	Plasma samples of delirium cases (CAM+) and non-delirium controls (CAM-) were
625	retrieved from the biorepository for subsequent proteomic analysis (3). Samples were
626	immunodepleted, digested and labeled with multiplex isobaric quantification (TMT)
627	reagents. For each set of TMT reagents, two channels were reserved for bridge
628	samples for post-hoc batch correction (4). TMT-labeled samples were concatenated (5)
629	and additionally fractionated (6) prior to LC-MS/MS (7) for quantification at MS3 (8).
630	After peptide spectral matching and false discovery rate (FDR) curation, the final
631	dataset of 3803 proteins was quantified and analyzed for candidate biomarkers (9).
622	

- 632
- 633

634 Figure 2 Caption:

A. Total number of proteins identified per batch. Bars are demarcated by the
 number of unique peptides used for protein identification. Gray portion of each
 barchart represents proteins identified by only a single peptide, highlighting the
 scope of one-hit proteins in our analysis.

639 **B.** Number of proteins identified in a cumulative number of experimental batches.

640 For example, of the 1638 total proteins identified in up to two cumulative batches

of experiments (cumulative batch \leq 2), about 90% of those (*n* = 1470) were one-

642 hit proteins. The number of one-hit proteins increases only marginally with

- 643 increasing cumulative batches (light green portion of the green bars), in contrast644 to proteins identified from at least two peptides.
- 645 **C.** Chromatographic retention times of select peptides from the discovery
- 646 experiment. Plot shows the consistency of retention times (RT) of
- 647 K.GTEAAGAMFLEAIPMSIPPEVK.F (blue rectangle), observed in two fractions
- 648 from multiple LC-MS runs. K.GTEDFIVESLDASFR.Y (red rectangle), on the
- other hand, was only identified once. In the absence of additional peptides, these
- single peptides required further information to reduce false protein assignments
- **D.** Scatter plot of experimental and predicted RTs of peptides from experimental
- batch 1. RTs were predicted by training a deep learning RT predictor, DeepRT+.
- 653 Prediction performance is assessed with R^2 and $\Delta t_{95\%}$ (red dashed lines). up =
- 654 number of unique peptides trained.
- E. Selection of the final 1731 proteins for downstream differential abundance
 analysis. Use of DeepRT+ salvaged 495 one-hit proteins that would otherwise be
 removed from downstream analysis.
- F. Dynamic range of all 1731 proteins, ranked in decreasing order of intensity. Each dot represents the median intensity of all intensity values recorded for a given protein across all samples. Intensity is plotted on the log-scale and spans 6.3 orders of magnitude between the high-abundance classical plasma proteins and the low-abundance signaling proteins. Functional groups are based on Putnam's classification. Red dots highlight representative members in each functional group. Labels are gene names of the corresponding proteins
- 665

666 667 **Figure 3 Caption:**

668	Α.	Principal component analysis of all discovery samples (including replicates).
669		Clustering is based on a subset of 64 proteins identified by the penalized
670		regression approach (ElasticNet) for feature selection.
671	В.	Hierarchically clustered heatmap of proteomic signatures of delirium cases and
672		non-delirium controls at two time points (baseline and post-operative day 1,
673		PO1). Post-operatively, a subset of proteins (protein cluster 2, dashed lines)
674		shows a higher expression in cases relative to non-cases, although the
675		expression of this subset of proteins was very similar between the two groups at
676		baseline
677	C.	Volcano plot of p -value (log ₁₀ scale) vs fold-change (log ₂ scale) of the 47 proteins
678		that explain most of the variation in proteomic profiles of the baseline and post-
679		operative day 1 samples. Blue dot means protein is significantly different at PO1
680		relative to baseline by at least 2 folds (p -value cut-off = 0.05)
681	D.	Volcano plot of the 64 proteins that explain most of the variation in proteomic
682		profiles between delirium cases and non-delirium controls.
683	E.	Diagnostic accuracy of the panel of 11 differentially abundant proteins that
684		discriminate cases from non-cases.
685	F.	Functional analysis of biomarkers for biological processes enriched among the
686		panel of 11 differentially abundant proteins that discriminate cases from non-
687		cases.
688		
689		

690 Figure 4 Caption: Biomarker Validation

691	Validation samples included baseline (B), post-bypass (P-BP) and post-operative day 1
692	(PO1) samples. To each unlabeled validation sample, an equimolar amount of CDS1, a
693	protein from S. pombe with no sequence overlap to human proteins previously
694	expressed and purified from bacteria, was added as a reference standard to control for
695	run-to-run variations. Select tryptic peptides of regulated proteins from the discovery
696	phase were targeted for quantification using via PRM-MS. Concentrations of each
697	biomarker were analyzed for changes across the sampling time points (B, PB, PO1).
698	Hypothetical data are depicted as exemplars.
699	
700	
701	Figure 5 Caption:
702	A. Normalized peak areas of CNDH2_HUMAN condensin subunit with increasing
703	concentrations of its heavy-labeled stable isotope standards spiked into a
704	background matrix of plasma. Grey area is the 95% confidence band of the
705	regression line of fit: $y = (12.84 + 33.25x[CNDH2]) \times 10^{6}$
706	B. Number of precursors monitored concurrently during five-minute windows across
707	the 78-minute gradient for used for validation experiments.
708	C. Representative extracted ion chromatogram (XIC): the five most intense
709	fragment ions of the CRP_HUMAN peptide ESDTSYVSLK, co-eluting at
710	28.3mins. All other peptides were quantified similarly with a minimum of five
711	transitions consistent across all samples, a minimum dot product (dotp) of 95%

- and manual inspection for distinct peak boundaries and interference-freetransitions.
- 714 **D.** Principal component analysis of all validation samples. Notable here is the
- clustering of post-bypass samples together with the baseline, signaling similar
- 716 proteomic signatures between the two timepoints.
- **E.** Representative plot of differential abundance analysis of validated proteins for
- the candidate biomarker C-reactive protein (CRP), showing changes across the
- three sample collection time points: baseline, post-bypass (P-BP) and post-
- operative day one (PO1)
- **F.** ROC analysis of the discriminatory power of the validated panel of biomarkers

722

723

724 **Table Captions:**

- 1. Selected baseline characteristics of study subject in the discovery phase.
- 726 Delirium cases were age- and sex-matched to non-delirium controls. Details of all
- 727 clinical characteristics of study subjects are reported elsewhere (Shaefi et al.,
- 728 2021). Abbreviations: *t*MOCA: telephone-based Montreal Cognitive Assessment
- 729 test for Dementia
- 2. Summary of DeepRT+ training parameters and results of prediction assessment.
- 731 Training. Given that each batch of sample has unique LC-MS experimental
- 732 conditions that uniquely impact RT, seven different models were built for each of
- the seven batches of experiments. Abbreviations: RT (min): minimum RT for the
- batch; RT (max): maximum RT; aa: amino acid; up (training): number of unique
- peptides trained; up (predicted): number of unique peptides whose RTs were
- predicted; R^2 : coefficient of determination = correlation coefficient for bivariate
- 737 analysis; Δt95%: deviations between observed and predicted RT that contains
- 738 95% of peptides for a given batch of experiment.
- 739 3. Discovery proteomics data
- 4. Condensin subunit (NCAPH2) linearity assessment
- 5. List of target peptides for PRM and instrument parameters
- 742
- 743

744 Supplemental Figures:

- **1.** Chromatographic retention times of select peptides, showing consistency of RT
- and adjacency of sample fractions from which they were identified
- 747 **2.** Scatter plot of experimental and predicted RTs of peptides from experimental
- batch 2 7. *up* = number of unique peptides trained
- **3.** Functional analysis of biomarkers for enriched cellular components
- **4.** Normalized peak areas of CNDH2_HUMAN condensin subunit, superimposed
- 751 with CDS1-SCHPO against increasing concentrations of its heavy-labeled stable
- isotope standards spiked into a background matrix of plasma.
- **5.** Flowchart of PRM method development
- 6. Differential abundance analysis of validated proteins, showing changes across
- the three sample collection time points: baseline, post-bypass (P-BP) and post-
- ⁷⁵⁶ operative day one (PO1). [†]: SAA1 and SAA2 could not be distinguished in the
- validation phase as none of the peptides unique to them met the quantification
- 758 criteria.
- 759
- 760
- 761
- 762
- 763
- 764
- 765

,00

766

767 References

768 769	1.	Armstrong, S.C., K.L. Cozza, and K.S. Watanabe, <i>The misdiagnosis of delirium</i> . Psychosomatics, 1997. 38 (5): p. 433-439.
770	2.	Inouye, S.K., et al., Nurses' recognition of delirium and its symptoms: comparison of
771		nurse and researcher ratings. Archives of internal medicine, 2001. 161(20): p. 2467-
772		2473.
773	3.	Ely, E.W., et al., Current opinions regarding the importance, diagnosis, and management
774		of delirium in the intensive care unit: a survey of 912 healthcare professionals. Critical
775		care medicine. 2004. 32 (1): p. 106-112.
776	4.	Brown IV. C.H., <i>Delirium in the cardiac suraical intensive care unit</i> . Current opinion in
777		anaesthesiology. 2014. 27 (2): p. 117.
778	5.	Inouve, S.K., R.G. Westendorp, and J.S. Saczynski, <i>Delirium in elderly people</i> . The Lancet,
779		2014. 383 (9920): p. 911-922.
780	6.	Brown IV, C.H., et al., The impact of delirium after cardiac surgical procedures on
781		postoperative resource use. The Annals of Thoracic Surgery, 2016. 101 (5): p. 1663-1669.
782	7.	Crocker, E., et al., Long-term effects of postoperative delirium in patients undergoing
783		cardiac operation: a systematic review. The Annals of thoracic surgery, 2016. 102 (4): p.
784		1391-1399.
785	8.	Newman, M.F., et al., Longitudinal assessment of neurocognitive function after
786		coronary-artery bypass surgery. New England Journal of Medicine, 2001. 344(6): p. 395-
787		402.
788	9.	Kálmán, J., et al., Elevated levels of inflammatory biomarkers in the cerebrospinal fluid
789		after coronary artery bypass surgery are predictors of cognitive decline. Neurochemistry
790		International, 2006. 48 (3): p. 177-180.
791	10.	Kozora, E., et al., Cognitive outcomes after on-versus off-pump coronary artery bypass
792		<i>surgery</i> . The Annals of thoracic surgery, 2010. 90 (4): p. 1134-1141.
793	11.	Saczynski, J.S., et al., Cognitive trajectories after postoperative delirium. N Engl J Med,
794		2012. 367 (1): p. 30-9.
795	12.	Rudolph, J.L., et al., Delirium: an independent predictor of functional decline after
796		<i>cardiac surgery.</i> Journal of the American Geriatrics Society, 2010. 58 (4): p. 643-649.
797	13.	Martin, BJ., et al., Delirium: a cause for concern beyond the immediate postoperative
798		<i>period</i> . The Annals of thoracic surgery, 2012. 93 (4): p. 1114-1120.
799	14.	Sugimura, Y., et al., Risk and consequences of postoperative delirium in cardiac surgery.
800		The Thoracic and Cardiovascular Surgeon, 2020. 68 (05): p. 417-424.
801	15.	Kishi, Y., et al., Delirium: patient characteristics that predict a missed diagnosis at
802		psychiatric consultation. General hospital psychiatry, 2007. 29 (5): p. 442-445.
803	16.	de la Cruz, M., et al., The frequency of missed delirium in patients referred to palliative
804		care in a comprehensive cancer center. Supportive Care in Cancer, 2015. 23(8): p. 2427-
805		2433.
806	17.	Wiredu, K., et al., Proteomics for the discovery of clinical delirium biomarkers: A review
807		of major contributions. 2022.

808 18. Maldonado, J.R., *Delirium pathophysiology: An updated hypothesis of the etiology of*809 *acute brain failure.* International Journal of Geriatric Psychiatry, 2018. 33(11): p. 1428810 1457.

- 811 19. Oldham, M.A., J.H. Flaherty, and J.R. Maldonado, *Refining delirium: a transtheoretical*812 *model of delirium disorder with preliminary neurophysiologic subtypes.* The American
 813 Journal of Geriatric Psychiatry, 2018. 26(9): p. 913-924.
- Dillon, S.T., et al., *Higher C-Reactive Protein Levels Predict Postoperative Delirium in Older Patients Undergoing Major Elective Surgery: A Longitudinal Nested Case-Control Study.* Biol Psychiatry, 2017. **81**(2): p. 145-153.
- Lindblom, R.P.F., et al., Protein Profiling in Serum and Cerebrospinal Fluid Following
 Complex Surgery on the Thoracic Aorta Identifies Biological Markers of Neurologic Injury.
 J Cardiovasc Transl Res, 2018. 11(6): p. 503-516.
- 820 22. Vasunilashorn, S., et al., A Multi-Protein Signature of Postoperative Delirium. Innovation
 821 in Aging, 2018. 2(suppl 1): p. 571-572.
- van Ton, A.P., et al., Downregulation of synapse-associated protein expression and loss
 of homeostatic microglial control in cerebrospinal fluid of infectious patients with
 delirium and patients with Alzheimer's disease. Brain, Behavior, and Immunity, 2020. 89:
 p. 656-667.
- Vasunilashorn, S., et al., Proteome-Wide Analysis using SOMAscan Identifies and
 Validates Chitinase-3-Like Protein 1 as a Risk and Disease Marker of Delirium Among
 Older Adults Undergoing Major Elective Surgery. The Journals of gerontology. Series A,
 Biological Sciences and Medical Sciences, 2021.
- Rhee, J., et al., Serum Proteomics of Older Patients Undergoing Major Cardiac Surgery: *Identification of Biomarkers Associated With Postoperative Delirium*. Frontiers in Aging
 Neuroscience, 2021. 13: p. 699763.
- 83326.McKay, T., et al., Preliminary Study of Serum Biomarkers Associated With Delirium After834Major Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia, 2021.
- 835 27. Han, Y., et al., Proteomic Analysis of Preoperative CSF Reveals Risk Biomarkers of
 836 Postoperative Delirium. Front Psychiatry, 2020. **11**: p. 170.
- 83728.Shaefi, S., et al., Intraoperative Oxygen Concentration and Neurocognition after Cardiac838Surgery: A Randomized Clinical Trial. Anesthesiology, 2021. 134(2): p. 189-201.
- 839 29. Grassetti, A.V., R. Hards, and S.A. Gerber, Offline pentafluorophenyl (PFP)-RP
 840 prefractionation as an alternative to high-pH RP for comprehensive LC-MS/MS
 841 proteomics and phosphoproteomics. Analytical and bioanalytical chemistry, 2017.
 842 409(19): p. 4615-4625.
- 84330.Ma, C., et al., Improved peptide retention time prediction in liquid chromatography844through deep learning. Analytical chemistry, 2018. **90**(18): p. 10881-10888.
- 84531.Zou, H. and T. Hastie, Regularization and variable selection via the elastic net. Journal of846the royal statistical society: series B (statistical methodology), 2005. 67(2): p. 301-320.
- 847 32. Gerber, S.A., et al., Absolute quantification of proteins and phosphoproteins from cell
 848 *lysates by tandem MS.* Proceedings of the National Academy of Sciences, 2003. 100(12):
 849 p. 6940-6945.

850 851 852	33.	Kettenbach, A.N., J. Rush, and S.A. Gerber, <i>Absolute quantification of protein and post-</i> <i>translational modification abundance with stable isotope–labeled synthetic peptides.</i> Nature protocols, 2011, 6(2); p. 175-186.
853	34.	Geyer, P.E., et al., Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol,
854		2017. 13 (9): p. 942.
855 856	35.	Pol, R.A., et al., <i>C-reactive protein predicts postoperative delirium following vascular surgery</i> . Annals of vascular surgery, 2014. 28 (8): p. 1923-1930.
857 858 859	36.	Liu, X., Y. Yu, and S. Zhu, Inflammatory markers in postoperative delirium (POD) and cognitive dysfunction (POCD): A meta-analysis of observational studies. PLoS One, 2018. 13 (4): n. e0195659
860	37	Peng Let al Preoperative C-Reactive Protein/Albumin Ratio a Risk Factor for
861	57.	Postoperative Delirium in Elderly Patients After Total Joint Arthroplasty Arthroplasty
862		2019. 34 (11): p. 2601-2605.
863	38.	Jiang, L. and G. Lei, Albumin/fibrinogen ratio, an independent risk factor for
864		postoperative delirium after total joint arthroplasty. Geriatrics & Gerontology
865	• •	International, 2022.
866	39.	Uhlar, C.M. and A.S. Whitehead, Serum amyloid A, the major vertebrate acute-phase
867		reactant. European journal of biochemistry, 1999. 265 (2): p. 501-523.
868	40.	Sack, G.H., Serum amyloid A–a review. Molecular Medicine, 2018. 24(1): p. 1-27.
869	41.	Liang, Js., et al., Evidence for local production of acute phase response apolipoprotein
870		serum amyloid A in Alzheimer's disease brain. Neuroscience letters, 1997. 225(2): p. 73-
871		
872 873	42.	Gabay, C. and I. Kushner, Acute-phase proteins and other systemic responses to inflammation. New England journal of medicine, 1999. 340 (6): p. 448-454.
874	43.	Barbierato, M., et al., Expression and differential responsiveness of central nervous
875		system glial cell populations to the acute phase protein serum amyloid A. Scientific
876		reports, 2017. 7(1): p. 1-14.
877	44.	Facci, L., et al., Serum amyloid A primes microglia for ATP-dependent interleukin-16
878		release. Journal of Neuroinflammation, 2018. 15 (1): p. 1-11.
879	45.	Jang, W.Y., et al., Overexpression of serum amyloid a 1 induces depressive-like behavior
880		<i>in mice</i> . Brain Research, 2017. 1654 : p. 55-65.
881	46.	Jang, S., et al., Serum amyloid A1 is involved in amyloid plaque aggregation and memory
882		<i>decline in amyloid beta abundant condition</i> . Transgenic Research, 2019. 28 (5): p. 499-
883		508.
884	47.	Matsumoto, J., et al., Serum amyloid A-induced blood-brain barrier dysfunction
885		associated with decreased claudin-5 expression in rat brain endothelial cells and its
886		inhibition by high-density lipoprotein in vitro. Neuroscience Letters, 2020. 738 : p.
887		135352.
888	48.	Zhang, Y., et al., Elevated Serum Amyloid A Is Associated With Cognitive Impairment in
889		Ischemic Stroke Patients. Frontiers in Neurology, 2021. 12 .
890	49.	Mueller-Steiner, S., et al., Antiamyloidogenic and neuroprotective functions of cathepsin
891		<i>B: implications for Alzheimer's disease</i> . Neuron, 2006. 51 (6): p. 703-714.
892 893	50.	Sundelöf, J., et al., <i>Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls.</i> Journal of Alzheimer's Disease, 2010. 22 (4): p. 1223-1230.

89451.Rong, X., et al., Chronic periodontitis and Alzheimer disease: a putative link of serum895proteins identification by 2D-DIGE proteomics. Frontiers in aging neuroscience, 2020: p.896248.

- Hook, V., et al., *Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders*. Biochimica et Biophysica Acta (BBA)-Proteins
 and Proteomics, 2020. **1868**(8): p. 140428.
- Hook, G., V. Hook, and M. Kindy, The cysteine protease inhibitor, E64d, reduces brain
 amyloid-& and improves memory deficits in Alzheimer's disease animal models by
 inhibiting cathepsin B, but not BACE1, & secretase activity. Journal of Alzheimer's
 disease, 2011. 26(2): p. 387-408.
- 904 54. Barrett, A.J., J.F. Woessner, and N.D. Rawlings, *Handbook of Proteolytic Enzymes*,
 905 *Volume 1*. Vol. 1. 2012: Elsevier.
- 906 55. Haj-sheykholeslami, A., et al., Serum pepsinogen I, pepsinogen II, and gastrin 17 in
 907 relatives of gastric cancer patients: comparative study with type and severity of gastritis.
 908 Clinical Gastroenterology and Hepatology, 2008. 6(2): p. 174-179.
- 909 56. He, C.y., et al., Serum pepsinogen II: a neglected but useful biomarker to differentiate
 910 between diseased and normal stomachs. Journal of gastroenterology and hepatology,
 911 2011. 26(6): p. 1039-1046.
- 912 57. Cao, X.-Y., et al., Serum pepsinogen II is a better diagnostic marker in gastric cancer.
 913 World journal of gastroenterology: WJG, 2012. 18(48): p. 7357.
- 914 58. Huang, Y.-k., et al., Significance of serum pepsinogens as a biomarker for gastric cancer
 915 and atrophic gastritis screening: a systematic review and meta-analysis. PloS one, 2015.
 916 10(11): p. e0142080.
- 91759.Thayer, J.F., Vagal tone and the inflammatory reflex. Cleveland Clinic journal of918medicine, 2009. **76**: p. S23-6.
- 60. Cerejeira, J., et al., *The cholinergic system and inflammation: common pathways in*920 *delirium pathophysiology.* Journal of the American Geriatrics Society, 2012. **60**(4): p.
 921 669-675.
- 922 61. Weber, C.S., et al., Low vagal tone is associated with impaired post stress recovery of
 923 cardiovascular, endocrine, and immune markers. European journal of applied
 924 physiology, 2010. 109(2): p. 201-211.
- 925 62. Johnson, R.L. and C.G. Wilson, A review of vagus nerve stimulation as a therapeutic
 926 intervention. Journal of inflammation research, 2018. 11: p. 203.
- 92763.Janowitz, H.D. and F. Hollander, Relation of uropepsinogen excretion to gastric pepsin928secretion in man. Journal of Applied Physiology, 1951. 4(2): p. 53-56.
- 84. Rolfson, D.B., et al., *Incidence and risk factors for delirium and other adverse outcomes in older adults after coronary artery bypass graft surgery*. The Canadian journal of
 cardiology, 1999. 15(7): p. 771-776.
- 932 65. O'neal, J.B., et al., *Risk factors for delirium after cardiac surgery: a historical cohort study*933 *outlining the influence of cardiopulmonary bypass.* Canadian Journal of
 934 Anesthesia/Journal canadien d'anesthésie, 2017. 64(11): p. 1129-1137.
- 935 66. Ordóñez-Velasco, L.M. and E. Hernández-Leiva, *Factors associated with delirium after*936 *cardiac surgery: a prospective cohort study*. Annals of Cardiac Anaesthesia, 2021. 24(2):
 937 p. 183.

938	67.	Norkiene, I., et al., Incidence and precipitating factors of delirium after coronary artery
939		<i>bypass grafting.</i> Scandinavian Cardiovascular Journal, 2007. 41 (3): p. 180-185.
940	68.	Bucerius, J., et al., Predictors of delirium after cardiac surgery delirium: effect of beating-
941		<i>heart (off-pump) surgery</i> . The Journal of thoracic and cardiovascular surgery, 2004.
942		127 (1): p. 57-64.
943	69.	Banfi, C., et al., Proteomic analysis of plasma from patients undergoing coronary artery
944		bypass grafting reveals a protease/antiprotease imbalance in favor of the serpin $lpha$ 1-
945		<i>antichymotrypsin</i> . Journal of proteome research, 2010. 9 (5): p. 2347-2357.
946	70.	Clendenen, N., et al., Correlation of pre-operative plasma protein concentrations in
947		cardiac surgery patients with bleeding outcomes using a targeted quantitative
948		proteomics approach. PROTEOMICS–Clinical Applications, 2017. 11 (7-8): p. 1600175.
949	71.	Fong, T.G., et al., Identification of Plasma Proteome Signatures Associated With Surgery
950		Using SOMAscan. Ann Surg, 2021. 273 (4): p. 732-742.
951	72.	Holmes, C., et al., Systemic inflammation and disease progression in Alzheimer disease.
952		Neurology, 2009, 73 (10): p. 768-774.
953	73.	Vasunilashorn, S.M., et al., Cytokines and postoperative delirium in older patients
954		undergoing major elective surgery. Journals of Gerontology Series A: Biomedical
955		Sciences and Medical Sciences, 2015, 70 (10): p. 1289-1295.
956	74.	Oh. E.S., et al., Sex differences in hip fracture surgery; preoperative risk factors for
957		delirium and postoperative outcomes. Journal of the American Geriatrics Society. 2016.
958		64 (8): p. 1616-1621.
959	75.	Kotfis, K., et al., The practical use of white cell inflammatory biomarkers in prediction of
960		postoperative delirium after cardiac surgery. Brain Sciences, 2019, 9 (11).
961	76.	Liotta, L.A. and E.F. Petricoin. Mass Spectrometry–Based Protein Biomarker Discovery:
962	,	Solving the Remaining Challenges to Reach the Promise of Clinical Benefit, Clinical
963		chemistry 2010, 56 (10): p. 1641-1642.
964	77.	Rifai, N., M.A. Gillette, and S.A. Carr. Protein biomarker discovery and validation: the
965		long and uncertain path to clinical utility. Nat Biotechnol. 2006. 24 (8): p. 971-83
966	78	Paulovich A G et al. The interface between biomarker discovery and clinical validation.
967	/01	the tar nit of the protein biomarker nipeline PROTEOMICS-Clinical Applications 2008
968		2 (10-11) [•] n 1386-1402
969	79	Whiteaker I.B. et al. An automated and multiplexed method for high throughput
970	/31	nentide immunoaffinity enrichment and multiple reaction monitoring mass
971		spectrometry-based quantification of protein biomarkers. Molecular & Cellular
972		Proteomics $2010 \ 9(1)$; p 184-196
972	80	Shaefi S et al Intraoperative ovugen concentration and neurocognition after cardiac
071	00.	surgeny: study protocol for a randomized controlled trial Trials 2017 18 (1): p. 600
075	Q 1	Eng. LK. T.A. Jahan and M.P. Hoonmann, Comet: an open source MS/MS sequence
976	01.	database search tool Proteomics 2013 13 (1): n 22-24
	00	Sonnar ME Duthon: a programming language for software integration and
977	02.	development Mol Graph Model 1999 17(1): n 57.61
370 070	00	R Coro Toom P: A Language and Environment for Statistical Computing in P Foundation
3/3	05.	for Statistical Computing, 2012: Vienne, Austria
980		jor Statistical Computing. 2013: Vienna, Austria.

- 981 84. Ward Jr, J.H., *Hierarchical grouping to optimize an objective function*. Journal of the
- 982 American statistical association, 1963. **58**(301): p. 236-244.
- 983 85. MacLean, B., et al., Skyline: an open source document editor for creating and analyzing
 984 targeted proteomics experiments. Bioinformatics, 2010. 26(7): p. 966-968.

985













Select Peptide Sequences







Concentration of heavy-labeled peptides of CNDH2_HUMAN in Plasma





23-

22

21[.]

Baseline

0

PO₁

Baseline

P-BP

25

24



P-BP

 \bigcirc

P01

